Choosing the right contraception

Authors

  • Pimpat Chawarntunpipat Family Planning and Reproductive Health Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University
  • Unnop Jaisamrarn Family Planning and Reproductive Health Unit, Department of Obstetrics and Gynecology, King Chulalongkorn Memorial Hospital
  • Somsook Santibenchakul Family Planning and Reproductive Health Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University

Keywords:

contraception, unintended pregnancy, efficacy, effectiveness, non-contraceptive benefits

Abstract

Abstract
Choosing the right contraception is a crucial strategy to prevent unintended pregnancies. Appropriate contraceptive methods for each woman should be highly effective in preventing pregnancy, safe and with fewer side effects, and other benefits beside contraceptive benefits. In terms of contraceptive efficacy comparison, the Life table analysis is more appropriate than the Pearl index, because this index considers the time when women use contraceptives. Generally, reproductive-aged women are healthy, so the risk of using contraceptives are very low. However, women with medical diseases might pose a serious risk in terms of using contraception. Therefore, it was recommended that healthcare providers should take a detailed medical history, current medicine usage and to perform a physical examination to assess their risk in the use of each contraceptive method. The risks of using hormonal contraceptives, such as cardiovascular diseases, cerebrovascular diseases and deep vein thrombosis are rare, especially with modern, low-dose hormonal contraception. Healthcare providers should provide information about the common side effects of each contraceptive method and non-contraceptive benefit for clients. This information may help clients decide to initiate and continue their use of contraception.



Downloads

Download data is not yet available.

References

Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008- 2011. N Engl J Med 2016;374:843-52.

Wattanakamolchai P, Sophonsritsuk A, Werawatakul Y, et al. The prevalence of unplanned pregnancy at antenatal care clinic. Srinagarind Med J 2018;33:408-14.

Woman’s Health Advocacy Foundation [Internet]. Bangkok: Unintended pregnancy in Thailand; 2006 [cited 2020 June 21]. [Available from: https://www.hiso.or.th/ hiso/picture/reportHealth/ThaiHealth 2006/THAI2006-Health-Indicators2.pdf].

Allen RH, Cwiak C. Contraception for the Medically Challenging Patient. 1st ed. New York: Springer: 2014; p.1-375.

Jensen JTC, Mitchell D. Speroff & Darney’s Clinical guide to contraception. 2019:1-30.

Kowal D, Hatcher RA, Nelson AL, et al. (Editors). Contraceptive technology. 21st edition: Managing Contraception, LLC; 2018.

Jaisamrarn U, Santipap M, Santibenchakul S. Discontinuation rates of diferentcontraceptive methods in Thai women up to 1-year after method initiation. Scientifc Reports 2021;11:10819.

Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016;65:1-103.

World Health O. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: World Health Organization; 2015.

Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004;190:S5-22.

Centers for Disease Control and Prevention (CDC). Prevalence of stroke-United States, 2006-2010. MMWR Morb Mortal Wkly Rep 2012;61:379-82.

Bousser MG, Conard J, Kittner S, et al. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on Combined Oral Contraceptives & Hormone Replacement Therapy. Cephalalgia 2000;20:155-6.

Tepper NK, Whiteman MK, Zapata LB, et al. Safety of hormonal contraceptives among women with migraine: A systematic review. Contraception. 2016;94:630-40.

Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. J Fam Plann Reprod Health Care 2010;36:33-8.

Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-9.

ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453-72.

Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008;83:97-102.

Hennessy S, Berlin JA, Kinman JL, et al. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception 2001;64:125-33.

Dragoman MV, Tepper NK, Fu R, et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet 2018;141:287-94.

Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone - containingoral contraceptives: a population-based cohort study. Cmaj 2011;183:E1319-25.

Weill A, Dalichampt M, Raguideau F, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ 2016;353:i2002.

Krauss RM, Burkman RT Jr. The metabolic impact of oral contraceptives. Am J Obstet Gynecol 1992;167:1177-84.

Lobo RA, Skinner JB, Lippman JS, et al. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertil Steril 1996;65:1100-9.

Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990;323:1375-81.

Dragoman M, Curtis KM, Gaffield ME. Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes. Contraception 2016;94:280-7.

Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361:1159-67.

Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2013;

:1931-43.

Ramachandran B. Functional association of oestrogen receptors with HPV infection in cervical carcinogenesis. Endocr Relat Cancer 2017;24:R99-r108.

Moodley M, Sewart S, Herrington CS, et al. The interaction between steroid hormones, human papillomavirus type 16, E6 oncogene expression, and cervical cancer. Int J Gynecol Cancer 2003;13:834-42.

Anastasiou E, McCarthy KJ, Gollub EL, et al. The relationship between hormonal contraception and cervical dysplasia/ cancer controlling for human papillomavirus infection: A systematic review. Contraception 2022;107:1-9.

Mørch LS, Skovlund CW, Hannaford PC, et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 2017;377:2228-39.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.

Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346: 2025-32.

Marchbanks PA, Curtis KM, Mandel MG, et al. Oral contraceptive formulation and risk of breast cancer. Contraception 2012;85:342-50.

Conz L, Mota BS, Bahamondes L, et al. Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2020;99:970-82.

Huber D, Seitz S, Kast K, et al. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet

;301:875-84.

Fruzzetti F, Fidecicchi T. Hormonal contraception and depression: Updated evidence and implications in clinical practice. Clin Drug Investig 2020;40: 1097-106.

Rapkin AJ, Korotkaya Y, Taylor KC. Contraception counseling for women with premenstrual dysphoric disorder (PMDD): current perspectives. Open Access J Contracept 2019;10:27-39.

Bengtsdotter H, Lundin C, Gemzell Danielsson K, et al. Ongoing or previous mental disorders predispose to adverse mood reporting during combined oral contraceptive use. Eur J Contracept Reprod Health Care 2018;23:45-51.

Both S, Lew-Starowicz M, Luria M, et al. Hormonal contraception and female sexuality: Position statements from the European Society of Sexual Medicine (ESSM). J Sex Med 2019;16:1681-95.

Malmborg A, Persson E, Brynhildsen J, et al. Hormonal contraception and sexual desire: A questionnaire-based study of young Swedish women. Eur J Contracept Reprod Health Care 2016;21:158-67.

Smith NK, Jozkowski KN, Sanders SA. Hormonal contraception and female pain, orgasm and sexual pleasure. J Sex Med 2014;11:462-70.

Stomati M, Genazzani AD, Petraglia F, et al. Contraception as prevention and therapy: sex steroids and the brain. Eur J Contracept Reprod Health Care 1998;3: 21-8.

Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995;51: 283-8.

Santibenchakul S, Jaisamrarn U. Acceptability, tolerability, and satisfaction of a contraceptive vaginal ring (the NuvaRing) among Thai women. Asian Biomed (Res Rev News) 2016;10:235-41.

Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009;91:1646-53.

Belsey EM. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception. 1988;38:181-206.

Schwallie PC, Assenzo JR. Contraceptive use - - efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 1973;24:331-9.

Amatayakul K, Sivasomboon B, Thanangkul O. A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception. 1980;22:605-22.

Bonny AE, Britto MT, Huang B, et al. Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA). J Pediatr Adolesc Gynecol 2004;17:109-15.

Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu- 380A IUD. Contraception. 1999;60:155-60.

Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol 2017;216:580. e1-.e9.

FFPRHC Guidance (April 2004). The levonorgestrel-releasing intrauterine system (LNG-IUS) in contraception and reproductive health. J Fam Plann Reprod Health Care 2004;30:99-108; quiz 9.

Serfaty D. Update on the contraceptive contraindications. J Gynecol Obstet Hum Reprod 2019;48:297-307.

Gynaecologists TFoSaRHotRCoOa. FSRH CEU clinical advice to support provision of effective contraception during the COVID-19 outbreak?; 2020.

Downloads

Published

2022-04-29

Issue

Section

Review Article (บทความวิชาการ)